(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM), a clinical-stage biopharmaceutical company developing targeted radiotherapies for cancer, said Thursday it has appointed Matt David as chief financial officer.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.